KALEN KNOPP: Open Payments
NPI 1184094344 · KIMBERLY, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$237 in 13 payments from 9 companies in 2025. Trend: 2023 $97 · 2024 $204 · 2025 $237
Food & beverage: $237
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $53 |
| Grifols USA, LLC | 1 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Amgen Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $15 |
| Medtronic, Inc. | 1 | $14 |
Products named: Prolastin-C Liquid, FARXIGA, MOUNJARO, Rybelsus, XIFAXAN, CAPLYTA, Ozempic, Wegovy.
Industry payments across ID — which companies pay providers there.
